Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2002-06-17
2009-06-16
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C558S156000
Reexamination Certificate
active
07547686
ABSTRACT:
A new and more efficient synthesis of combretastatin A-3 (2a) was completed (8.4% overall yield) starting from methyl gallate and isovanillin with aldehyde 5 and phosphonium salt 8 as key intermediates. Conversion of combretastatin A-3 (2a) to a series of diphosphate prodrugs (lOa-lOl) containing selected anions was achieved. Both the diphosphate sodium (lOa) and potassium salts (lOc) displayed aqueous solubility in excess of 220 mg/ml at room temperature and good cancer cell line inhibitory activity.
REFERENCES:
patent: 5561122 (1996-10-01), Pettit
patent: 5569786 (1996-10-01), Pettit et al.
patent: 0 276 051 (1988-07-01), None
patent: WO 99/35150 (1999-07-01), None
Pettit et al., Canadian Journal of Chemistry, vol. 65, pp. 2390-2396, (1987).
Pettit et al., Anti-Cancer Drug Design, vol. 13, pp. 981-993, (1998).
Grosios et al., British Journal of Cancer, vol. 81, No. 8, pp. 1318-1327, (1999).
Pettit et al., Anti-Cancer Drug Design, vol. 15, pp. 203-216, (2000).
Parkins et al., British Journal of Cancer, vol. 83, No. 6, pp. 811-816, (2000).
Pettit et al., Anti-Cancer Drug Design (1998), 13, 183-191.
Pettit et al., Anticancer Drug Des. (1995), 10(4), 299-309 (abstract only).
Pettit et al., “Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate prodrugs,” Anti-Cancer Drug Design, vol. 15, pp. 397-403, (2000).
Greenwald et al., “Drug Delivery Systems: Water Soluble Taxol 2′-Poly(ethylene glycol) Ester Prodrugs—Design and in Vivo Effectiveness”,J. Med. Chem., 39:424-431 (1996).
Lazar et al., “A Selective Removal of Benzyl Protecting Groups in Arylphosphate Esters with Bromotrimethylsilane”,Synthetic Communications, 22(6):923-931 (1992).
Mamber et al., “Tubulin Polymerization by Paclitaxel (Taxol) Phosphate Prodrugs after Metabolic Activation with Alkaline Phosphatase”,The Journal of Pharmacology and Experimental Therapeutics, 274(2):877-883 (1995).
Pettit et al., “Antineoplastic agents 460. Synthesis of Combretastatin A-2 Prodrugs”,Anti-Cancer Drug Design, 16:185-193 (2001).
Ueda et al., “Novel Water Soluble Phosphate Prodrugs of Taxol® Possessing In Vivo Antitumor Activity”,Bioorganic&Medicinal Chemistry Letters, 3(8):1761-1766 (1993).
Vyas et al., “Synthesis and Antitumor Evaluation of Water Soluble Taxol Phosphates”,Bioorganic&Medicinal Chemistry Letters, 3(6):1357-1360 (1993).
Office Action dated May 9, 2007 for corresponding EP application No. 02 746 550.9 (3 sheets).
Office Action dated Aug. 18, 2008 for corresponding EP application No. 02 746 550.9 (5 sheets).
Minardi Mathew D.
Pettit George R.
Anderson Rebecca L
Arizona Board of Regents, a body corporate of the State of Arizo
McAndrews Held & Malloy Ltd.
LandOfFree
Combretastatin A-3 prodrug does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combretastatin A-3 prodrug, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combretastatin A-3 prodrug will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4132607